Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 12,784.0 | 11,673.0 | 11,362.0 | 11,099.0 | 10,584.0 | 10,163.0 | 9,968.0 | 10,719.0 |
Revenue growth | 9.5% | 2.7% | 2.4% | 4.9% | 4.1% | 2.0% | -7.0% | 13.9% |
Cost of goods sold | 7,679.0 | 7,086.0 | 6,601.0 | 6,340.0 | 6,110.0 | 6,047.0 | 5,822.0 | 6,138.0 |
Gross profit | 5,105.0 | 4,587.0 | 4,761.0 | 4,759.0 | 4,474.0 | 4,116.0 | 4,146.0 | 4,581.0 |
Gross margin | 39.9% | 39.3% | 41.9% | 42.9% | 42.3% | 40.5% | 41.6% | 42.7% |
Selling, general and administrative | 2,867.0 | 2,469.0 | 2,535.0 | 2,620.0 | 2,627.0 | 2,725.0 | 3,094.0 | 3,315.0 |
Research and development | 534.0 | 521.0 | 595.0 | 654.0 | 615.0 | 646.0 | 603.0 | 610.0 |
EBITA | 2,002.0 | 1,836.0 | 1,955.0 | 1,753.0 | 1,409.0 | 908.0 | 607.0 | 825.0 |
EBITA margin | 15.7% | 15.7% | 17.2% | 15.8% | 13.3% | 8.9% | 6.1% | 7.7% |
Amortization of intangibles | 298.0 | 222.0 | 183.0 | 169.0 | 154.0 | 163.0 | 158.0 | 169.0 |
EBIT | 1,704.0 | 1,614.0 | 1,772.0 | 1,584.0 | 1,255.0 | 745.0 | 449.0 | 656.0 |
EBIT margin | 13.3% | 13.8% | 15.6% | 14.3% | 11.9% | 7.3% | 4.5% | 6.1% |
Pre-tax income | 1,477.0 | 1,292.0 | 970.0 | 1,617.0 | 1,100.0 | 4,954.0 | 428.0 | 490.0 |
Income taxes | 182.0 | 182.0 | -41.0 | 65.0 | 491.0 | -12.0 | 35.0 | 33.0 |
Tax rate | 12.3% | 14.1% | | 4.0% | 44.6% | | 8.2% | 6.7% |
Earnings from continuing ops | 1,284.0 | 1,102.0 | 1,001.0 | 3,104.0 | 1,218.0 | 4,966.0 | 393.0 | 457.0 |
Earnings from discontinued ops | | | | -6.0 | -7.0 | -1.0 | 575.0 | 2,040.0 |
Net income | 1,284.0 | 1,102.0 | 1,001.0 | 3,098.0 | 1,211.0 | 4,965.0 | 968.0 | 2,497.0 |
Net margin | 10.0% | 9.4% | 8.8% | 27.9% | 11.4% | 48.9% | 9.7% | 23.3% |
|
Diluted EPS | $2.53 | $2.13 | $1.93 | $5.68 | $2.19 | $9.01 | $0.72 | $0.84 |
Shares outstanding (diluted) | 508.0 | 517.0 | 519.0 | 546.0 | 555.0 | 551.0 | 549.0 | 547.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|